# ATRAID

## Overview
The ATRAID gene encodes the all-trans retinoic acid induced differentiation factor, a transmembrane protein that plays a pivotal role in the cellular response to nitrogen-containing bisphosphonates (N-BPs), which are commonly used in the treatment of bone diseases such as osteoporosis. This protein is integral to the regulation of osteoclast function and bone resorption, acting as a positive regulator of protein prenylation processes, which are crucial for the anti-proliferative effects of N-BPs on bone cells (Surface2020ATRAID; Surface2018ATRAIDregulates). ATRAID is characterized by its complex structure, including domains such as a signal peptide, Toll-like-receptor leucine-rich repeat, EGF-like domain, and a transmembrane domain, which facilitate its diverse functional roles within the endoplasmic reticulum and Golgi apparatus (Surface2020ATRAID). The gene's activity is essential for maintaining bone density and strength, and its deficiency can lead to resistance to N-BP treatment, highlighting its clinical significance in bone health (Surface2020ATRAID).

## Function
The ATRAID gene, also known as APR-3/C2orf28, encodes a protein that plays a critical role in the molecular responses to nitrogen-containing bisphosphonates (N-BPs), which are medications used to treat bone diseases such as osteoporosis. ATRAID is essential for the anti-proliferative effects of N-BPs on bone cells, particularly in the inhibition of osteoclast function, which is crucial for bone resorption (Surface2020ATRAID; Surface2018ATRAIDregulates). The protein is involved in the regulation of protein prenylation, a process affected by N-BP treatment, and acts as a positive regulator upstream of FDPS, influencing this process independently of apoptosis (Surface2020ATRAID; Surface2018ATRAIDregulates).

ATRAID is conserved in chordates and contains several domains, including a signal peptide, Toll-like-receptor leucine-rich repeat, EGF-like domain, and a transmembrane domain, indicating its complex structure and functional versatility (Surface2020ATRAID). In cellular biology, ATRAID is active in the endoplasmic reticulum and Golgi apparatus, where it influences cellular differentiation processes (Surface2018ATRAIDregulates). The gene's activity is crucial for maintaining bone density and strength, as demonstrated in models of osteoporosis, where ATRAID deficiency leads to resistance to the effects of N-BPs (Surface2020ATRAID).

## Clinical Significance
Mutations and alterations in the ATRAID gene have been associated with various adverse conditions, particularly in the context of treatment with nitrogen-containing bisphosphonates (N-BPs), which are used for bone diseases like osteoporosis. Patients with rare non-synonymous coding variants in ATRAID have shown hypersensitivity to N-BPs, leading to conditions such as atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ) (Surface2020ATRAID). Specifically, the D5G/G32R variant in ATRAID has been identified in patients experiencing these adverse effects, suggesting a genetic predisposition to poor outcomes with N-BP treatment (Surface2018ATRAIDregulates).

ATRAID is crucial for the cellular response to N-BPs, and its deficiency results in resistance to the cytotoxic effects of these drugs, as observed in both cell lines and animal models (Surface2020ATRAID; Surface2018ATRAIDregulates). This resistance is linked to impaired inhibition of osteoclast function, which is essential for the therapeutic action of N-BPs in osteoporosis treatment (Surface2020ATRAID). The gene's role in the regulation of protein prenylation, a key mechanism of N-BP action, further underscores its clinical significance (Surface2020ATRAID).


## References


[1. (Surface2020ATRAID) Lauren E. Surface, Damon T. Burrow, Jinmei Li, Jiwoong Park, Sandeep Kumar, Cheng Lyu, Niki Song, Zhou Yu, Abbhirami Rajagopal, Yangjin Bae, Brendan H. Lee, Steven Mumm, Charles C. Gu, Jonathan C. Baker, Mahshid Mohseni, Melissa Sum, Margaret Huskey, Shenghui Duan, Vinieth N. Bijanki, Roberto Civitelli, Michael J. Gardner, Chris M. McAndrew, William M. Ricci, Christina A. Gurnett, Kathryn Diemer, Fei Wan, Christina L. Costantino, Kristen M. Shannon, Noopur Raje, Thomas B. Dodson, Daniel A. Haber, Jan E. Carette, Malini Varadarajan, Thijn R. Brummelkamp, Kivanc Birsoy, David M. Sabatini, Gabe Haller, and Timothy R. Peterson. Atraid regulates the action of nitrogen-containing bisphosphonates on bone. Science Translational Medicine, May 2020. URL: http://dx.doi.org/10.1126/scitranslmed.aav9166, doi:10.1126/scitranslmed.aav9166. This article has 17 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/scitranslmed.aav9166)

2. (Surface2018ATRAIDregulates) ATRAIDregulates the action of nitrogen-containing bisphosphonates on bone. This article has 1 citations.